MelliCell, Inc.
Prince Nnah is an accomplished entrepreneur and healthcare executive with extensive experience in healthcare technology and management. As Co-Founder and CEO of MelliCell, Inc. since 2020, and Co-Founder/Chief Business Development Officer of IntelyCare since 2016, Prince Nnah has played a key role in disrupting the healthcare staffing industry with innovative solutions. Previous leadership positions include President and Founder of Beehive Management Group, where strategic consulting focused on healthcare solutions, and Chief Operating Officer at San Gorgonio Memorial Hospital, overseeing essential clinical departments and pharmacy operations. Education includes an Executive Education in Healthcare Value Measurement from Harvard Business School, a Doctorate in Pharmacology/Pharmacy from the Massachusetts College of Pharmacy and Health Sciences, and an MBA from the University of Southern California.
This person is not in any teams
MelliCell, Inc.
MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.